Amgen cancer vaccine due for FDA decision by Oct. 27; GAVI pledges top $7.5B;

> After a three-month delay in its FDA review, Amgen ($AMGN) is expecting a regulatory decision on its cancer vaccine, T-Vec, by Oct. 27. Release

> The GAVI Pledging Conference in Berlin saw new pledges totaling $7.54 billion. Report

> GlaxoSmithKline's ($GSK) Ebola vaccine is safe and generates an immune response, researchers have found. Report

> Three different recombinant protective antigen vaccines formulated with Immunovaccine's DepoVax tech protected animals against a lethal anthrax challenge after one vaccination. Release

> The OTC biotech Vaccinogen says it's closed a previously reported deal for $10 million to study its therapeutic cancer vaccine OncoVax. Release

> A unit of China's Hualan Biological has received government approval to run clinical trials of its H7N9 vaccine. Report

> Tau-based vaccines could transform early Alzheimer's disease treatment, according to GlobalData. Release

And Finally... "Customized soap bubbles" could transform vaccine delivery. More

 

 

Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.